CING
NASDAQ HealthcareCingulate Inc. - Common Stock
Biotechnology
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
�� 市场数据
| 价格 | $5.45 |
|---|---|
| 成交量 | 271,580 |
| 市值 | 66.77M |
| 贝塔系数 | -0.770 |
| RSI（14日） | 33.1 |
| 200日均线 | $4.89 |
| 50日均线 | $6.71 |
| 52周最高 | $11.89 |
| 52周最低 | $3.20 |
| Forward P/E | -3.75 |
| Price / Book | 15.75 |
🎯 投资策略评分
CING 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (85/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🎈 Over-Hyped (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 CING in your text
粘贴任何文章、记录或帖子 — 工具将提取 CING 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.